(Q34731421)

4 August 2017

1 reference

title

Therapeutic vaccines: realities of today and hopes for the future (English)

1 reference

4 August 2017

1 reference

2

Ruth Arnon

1 reference

4 August 2017

Michael Sela

1

1 reference

4 August 2017

Bilha Schechter

series ordinal

3

1 reference

4 August 2017

language of work or name

1 reference

1 June 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

7

1 reference

4 August 2017

issue

12

1 reference

4 August 2017

page(s)

664-673

1 reference

Glatiramer acetate in the treatment of multiple sclerosis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

The basis for HIV immunotherapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Peptide vaccines against hepatitis B virus: from animal model to human studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Tuberculosis DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Dendritic cells infected with Mycobacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

1 reference

7 January 2021

Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Antibody clears senile plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Immunomodulation of experimental autoimmune encephalomyelitis with ordered peptides based on MHC-TCR binding motifs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Regulation of Antibody Production by Helper T Cell Clones in Experimental Autoimmune Myasthenia Gravis Is Mediated by IL-4 and Antigen-Specific T Cell Factors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Peptide therapy for diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Beneficial immune activity after CNS injury: prospects for vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

T-cell vaccination for autoimmune disease: a panorama

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

1 reference

7 January 2021

Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Serological analysis of human tumor antigens: molecular definition and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2802%2902296-1

7 January 2021

10.1016/S1359-6446(02)02296-1

Identifiers

DOI

1 reference

4 August 2017

1 reference